MGI Tech Co., Ltd. Class A
SSSE:68811462.36
CNY
+0.10
(+0.16%)
ISIN
CNE100005PC8
Return %
Stock
S&P 500
1Y
-9.35
14.20
3Y
-20.71
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jian Liu
- Full Time Employees
- 2,195
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Shenzhen China
- IPO Date
- Sep 9, 2022
- Website
- mgi-tech.com
- Similar Companies
- Business
- MGI Tech Co., Ltd. is a China-based biotechnology and life science instrument company engaged in the research, development, manufacturing, and commercialization of genetic sequencing devices, laboratory automation equipment, and multi-omics technologies for clinical and scientific research applications. The company operates through three core business segments: Gene Sequencing, Laboratory Automation, and New Business. Its Gene Sequencing segment provides high-throughput and ultra-high-throughput genetic sequencers based on proprietary DNBSEQ DNA nanoball technology, including the DNBSEQ-T20x2, DNBSEQ-T7, DNBSEQ-G400, DNBSEQ-G99, and benchtop DNBSEQ-E25 platforms, as well as CycloneSEQ nanopore single-molecule sequencing instruments, library preparation kits, sequencing reagents, flow cells, and chemical consumables; its Laboratory Automation segment develops automated liquid handling workstations, automated nucleic acid extractors, and sample preparation systems, including the MGISP-960, MGISP-100, and MGISP-Smart 8 platforms, alongside automated ultra-low temperature biobank sample storage systems; and its New Business segment offers single-cell sequencing library preparation systems, spatial transcriptomics platforms, remote robotic tele-ultrasound systems such as the MGIUS-R3, and bioinformatics analysis software and hardware accelerators including MegaBOLT and Zsmart laboratory management suites. The company serves genomic research institutions, clinical diagnostic laboratories, hospitals, pharmaceutical companies, disease control centers, and agricultural breeding organizations across the Asia-Pacific, Europe, North America, the Middle East, Africa, and Latin America. Founded in 2016 and spun off from BGI Group, MGI Tech Co., Ltd. is headquartered in Shenzhen, China. In recent developments, the company has expanded its global commercial footprint across international markets, opened new Customer Experience Centers and regional hubs in Europe, the Americas, and the Asia-Pacific region, rolled out the ultra-high-throughput DNBSEQ-T20x2 platform designed to lower human whole-genome sequencing costs below the one-hundred-dollar threshold, launched the CycloneSEQ nanopore sequencing series to expand into long-read sequencing, and entered into multiple global strategic partnerships with international genomics service providers, healthcare networks, and academic research institutions to advance spatial multi-omics and high-throughput clinical diagnostics.